José Vivancos Mora-rekin lankidetzan egindako argitalpenak (20)

2023

  1. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

2018

  1. Farmacología de la enfermedad de Alzheimer y la enfermedad cerebrovascular. Fármacos psicoestimulantes y nootropos

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 311-324

2014

  1. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways

    Journal of Leukocyte Biology, Vol. 95, Núm. 4, pp. 587-598

2013

  1. Amelioration of Ischemic brain damage by peritoneal dialysis

    Journal of Clinical Investigation, Vol. 123, Núm. 10, pp. 4359-4363

  2. N2 neutrophils, novel players in brain inflammation after stroke: Modulation by the pparγ agonist rosiglitazone

    Stroke, Vol. 44, Núm. 12, pp. 3498-3508

  3. Neuronal excitotoxicity after carotid angioplasty and stent placement procedures

    Radiology, Vol. 268, Núm. 2, pp. 515-520

2012

  1. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection

    Stroke, Vol. 43, Núm. 1, pp. 211-219

2011

  1. Longitudinal studies of ischemic penumbra by using 18F-FDG PET and MRI techniques in permanent and transient focal cerebral ischemia in rats

    NeuroImage, Vol. 57, Núm. 1, pp. 45-54

2009

  1. Synthesis of lipoxin A 4 by 5-lipoxygenase mediates pparγ-dependent, neuroprotective effects of rosiglitazone in experimental stroke

    Journal of Neuroscience, Vol. 29, Núm. 12, pp. 3875-3884

2008

  1. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke

    Circulation, Vol. 118, Núm. 14, pp. 1450-1459

2007

  1. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in neuroprotection

    Journal of Cerebral Blood Flow and Metabolism, Vol. 27, Núm. 7, pp. 1327-1338

  2. Statin treatment withdrawal in ischemic stroke: A controlled randomized study

    Neurology, Vol. 69, Núm. 9, pp. 904-910

2006

  1. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke

    Journal of Experimental Medicine, Vol. 203, Núm. 3, pp. 711-717

  2. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions

    Cerebrovascular Diseases, Vol. 22, Núm. 2-3, pp. 123-129

  3. Ischemic preconditioning: A novel target for neuroprotective therapy

    Cerebrovascular Diseases, Vol. 21, Núm. SUPPL. 2, pp. 38-47

  4. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J 2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms

    Journal of Cerebral Blood Flow and Metabolism, Vol. 26, Núm. 2, pp. 218-229

2005

  1. Increased plasma levels of 15-deoxy Δ prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke

    Stroke, Vol. 36, Núm. 6, pp. 1189-1194

  2. The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke

    Journal of Neuropathology and Experimental Neurology, Vol. 64, Núm. 9, pp. 797-805

  3. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers

    Stroke, Vol. 36, Núm. 9, pp. 1921-1926

2003

  1. Revisión de consenso. Neuroprotección farmacológica en la isquemia cerebral: ¿Es todavía una opción terapéutica?

    Neurologia, Vol. 18, Núm. 7, pp. 368-384